Editorial
doi: 10.1200/JCO.2005.02.002.
Epub 2005 Jul 11.
Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck
- PMID: 16009959
- DOI: 10.1200/JCO.2005.02.002
Item in Clipboard
Editorial
Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck
J Clin Oncol.
.
No abstract available
Comment on
-
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.J Clin Oncol. 2005 Aug 20;23(24):5578-87. doi: 10.1200/JCO.2005.07.120. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009949 Clinical Trial.
-
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.J Clin Oncol. 2005 Aug 20;23(24):5568-77. doi: 10.1200/JCO.2005.07.119. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009950 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
